The clinical utility of a mixture of sulfated oligosaccharides (PI-88) with dual heparanase and angiogenic inhibitory activity has been previously demonstrated in a phase II clinical trial for hepatocellular carcinoma (HCC) (Liu et al, 2009). Here, HPSE is linked to hepatocellular carcinoma.